BridgeBio Pharma Inc (BBIO)
28.01
-0.84
(-2.91%)
USD |
NASDAQ |
May 31, 16:00
28.01
0.00 (0.00%)
After-Hours: 20:00
BridgeBio Pharma Research and Development Expense (Annual): 455.71M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 455.71M |
| December 31, 2022 | 399.46M |
| December 31, 2021 | 451.02M |
| December 31, 2020 | 337.05M |
| Date | Value |
|---|---|
| December 31, 2019 | 209.95M |
| December 31, 2018 | 140.07M |
| December 31, 2017 | 30.56M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
209.95M
Minimum
2019
455.71M
Maximum
2023
370.64M
Average
399.46M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Pfizer Inc | 10.68B |
| Alnylam Pharmaceuticals Inc | 1.004B |
| Regenxbio Inc | 232.27M |
| Arvinas Inc | 379.70M |
| IDEAYA Biosciences Inc | 129.51M |